| Revenue | — | — | — |
| Testing revenue | 418.96a | 326.54a | 250.54a |
| Product revenue | 13.65a | 15.59a | 12.63a |
| Biopharmaceutical and other revenue | 13.15a | 18.92a | 33.36a |
| Total revenue | 445.76a | 361.05a | 296.54a |
| Cost of revenue | — | — | — |
| Cost of testing revenue | -114.57a | -88.91a | -75.32a |
| Cost of product revenue | -9.11a | -8.67a | -7.82a |
| Cost of biopharmaceutical and other revenue | -12.38a | -15.32a | -18.45a |
| Intangible asset amortization - cost of revenue | -11.55a | -18.46a | -19.27a |
| Total cost of revenue | -147.62a | -131.37a | -120.86a |
| Gross profit | 298.15a | 229.68a | 175.68a |
| Operating expenses | — | — | — |
| Research and development | -69.29a | -57.31a | -40.6a |
| Selling and marketing | -95.43a | -101.49a | -97.56a |
| General and administrative | -110.61a | -86.23a | -73.2a |
| Impairment of long-lived assets | -3.37a | -68.35a | -3.32a |
| Intangible asset amortization - operating expenses | -3.3a | -2.11a | -2.08a |
| Total operating expenses | -282a | -315.48a | -216.76a |
| Income (loss) from operations | 16.14a | -85.8a | -41.08a |
| Other income, net | 9.6a | 9.18a | 4.65a |
| Income (loss) before income taxes | 25.74a | -76.61a | -36.43a |
| Income tax provision (benefit) | -1.61a | -2.21a | -0.13a |
| Net income (loss) | 24.14a | -74.4a | -36.56a |